Previous 10 | Next 10 |
2023-08-02 06:20:50 ET BeiGene press release ( NASDAQ: BGNE ): Q2 GAAP EPS of -$0.28 beats by $3.25 . Revenue of $595.26M (+74.3% Y/Y) beats by $79.9M . Global sales of BRUKINSA totaled $308 million in the quarter, a 139% increase from the prior-year period and...
Recorded total product revenue of $554 million in the quarter, an increase of 82% from the prior-year period, driven by increased sales of BRUKINSA ® worldwide Global sales of BRUKINSA totaled $308 million in the quarter, a 139% increase from the prior-year period and a 46% i...
2023-08-01 11:13:37 ET Major earnings expected before the bell on Wednesday include: CVS Health ( CVS ) The Kraft Heinz ( KHC ) Phillips 66 ( PSX ) Rithm Capital ( RITM ) Teva Pharmaceutical Industries ( TEVA ) For further details see: Not...
2023-07-30 01:20:34 ET Summary AstraZeneca's revenue for the second quarter of 2023 was $11.42 billion, up 5% from the previous quarter and 6% from the second quarter of 2022. At the end of June 2023, AstraZeneca's total debt was about $30.8 billion, down $1.68 billion from the pr...
2023-07-21 11:17:38 ET Chinese biotech BeiGene ( NASDAQ: BGNE ) said that its drug tislelizumab has received a positive opinion from an advisory committee of the European Medicines Agency for the treatment of advanced or metastatic esophageal squamous cell carcinoma after platinum-b...
BeiGene (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval for tislelizumab as monotherapy for the treat...
2023-07-14 15:00:24 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
- Submission seeks approval for BRUKINSA in combination with obinutuzumab as a treatment for relapsed or refractory follicular lymphoma BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has...
BeiGene acquires exclusive option for global license to investigational antibody drug conjugate; DualityBio to continue preclinical research activities and support Investigational New Drug filing BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, and Duali...
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will host an investor Research and Development Day in New York City and via webcast on July 18, 2023. John V. Oyler, BeiGene's Co-Founder, Chairman and CEO, along with the Compan...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...